Polymyositis and dermatomyositis natural history, complications and prognosis

Jump to navigation Jump to search

Polymyositis and dermatomyositis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Polymyositis and dermatomyositis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Polymyositis and dermatomyositis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polymyositis and dermatomyositis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polymyositis and dermatomyositis natural history, complications and prognosis

CDC on Polymyositis and dermatomyositis natural history, complications and prognosis

Polymyositis and dermatomyositis natural history, complications and prognosis in the news

Blogs on Polymyositis and dermatomyositis natural history, complications and prognosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Polymyositis and dermatomyositis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Natural History, Complications, and Prognosis

Natural History

  • The symptoms of polymyositis and dermatomyositis usually develop very slowly and progressively from proximal muscle weakness to distal muscle weakness.[1]
  • Patients with polymyositis and dermatomyositis usually present with proximal muscle weakness manifested as difficulty to raise their arms above the shoulders or from chair, or climbing stairs. Patients might experience myalgia and muscle tenderness in the early stages of polymyositis.
  • Polymyositis and dermatomyositis usually do not affect facial muscles.
  • In dermatomyositis, skin manifestations develop and after few months to years myositis will occur.

Complications

  • Common complications of polymyositis and dermatomyositis include:[2][3]
Polymyositis Dermatomyositis
Malignancy
  • Lung
  • Kidney
  • Breast
  • Bladder
  • Endometrial
  • Cervical
  • Thyroid
  • Lymphoma
  • Myeloma
  • Brain  
5-7 fold more risks than the general population
  • Lung
  • Ovarian
  • Breast
  • Colorectal
  • Cervical
  • Bladder
  • Nasopharyngeal
  • Esophageal
  • Pancreatic
  • Kidney
Cardiac
  • Arrhythmia
  • Conduction abnormalities
  • Cardiac arrest
  • Congestive heart failure (CHF)
  • Myocarditis
  • Pericarditis
  • Angina
  • Secondary fibrosis
Pulmonary
  • Hypoventilation and respiratory failure
  • Aspiration pneumonia
  • Interstitial lung disease
Gastrointestinal
  • Dysphagia
  • Proximal esophageal skeletal muscle dysfunction
Medication related
  • Osteoporosis
  • Myopathy
Infection
Factors associated with malignancy in patients with myositis
Increased risk of malignancy Decreased risk of malignancy
  • Older age at diagnosis
  • Male sex
  • Smoking
  • Skin disease
  • Leucocytoclastic vasculitis
  • Cutaneous necrosis
  • Resistance to therapy
  • Idiopathic pulmonary fibrosis  
  • Muscle disease
  • Dysphagia
  • Rapid onset of myositis
  • Rare-infiltrative type muscle pathology on muscle biopsy
  • Elevated inflammatory markers (ESR, CRP)
  • Elevated CK
  • Elevated tumor markers
  • Positive anti-TIF-1γ
  • Positive anti-NXP-2
  • Positive HLA-A28
  • Positive anti-HMGCR antibodies
  • Interstitial lung disease
  • Arthritis/arthralgia
  • Raynaud’s phenomenon
  • Positive antinuclear antibodies (ANA)
  • Positive anti-ENA antibodies
  • Positive anti-Jo-1 antibody

Prognosis

  • Prognosis of polymyositis and dermatomyositis varies depends on different studies.
  • Prognosis is generally poor, and the overall mortality rate of patients with polymyositis and dermatomyositis is approximately 22%.[4]
  • Five-year survival rates in polymyositis and dermatomyositis have been estimated at more than 80%. 
  • Polymyositis and dermatomyositis have a high morbidity rate in which patients would experience insignificant muscular disability after 3 years.
  • The presence of following complications and symptoms are associated with a particularly poor prognosis among patients with polymyositis and dermatomyositis:
    • Presence of extramuscular organ involvement
      • Cardiovascular involvement (one of the most common causes of death)
      • Pulmonary involvement (increased morbidity and mortality)
    • Older age of diagnosis
  • The presence of following characteristics are associated with a better prognosis among patients with polymyositis and dermatomyositis:[5]
    • Younger age of diagnosis
    • Shorter duration of clinical manifestations prior to therapy initiation

References

  1. Khan, Sabiha; Christopher-Stine, Lisa (2011). "Polymyositis, Dermatomyositis, and Autoimmune Necrotizing Myopathy: Clinical Features". Rheumatic Disease Clinics of North America. 37 (2): 143–158. doi:10.1016/j.rdc.2011.01.001. ISSN 0889-857X.
  2. Barnes BE, Mawr B (January 1976). "Dermatomyositis and malignancy. A review of the literature". Ann. Intern. Med. 84 (1): 68–76. PMID 1106291.
  3. Tiniakou, Eleni; Mammen, Andrew L. (2015). "Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review". Clinical Reviews in Allergy & Immunology. 52 (1): 20–33. doi:10.1007/s12016-015-8511-x. ISSN 1080-0549.
  4. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, Courtois H (October 2001). "Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis". J. Rheumatol. 28 (10): 2230–7. PMID 11669162.
  5. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, Courtois H (October 2001). "Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis". J. Rheumatol. 28 (10): 2230–7. PMID 11669162.